Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.50 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986499 | 1.00 | HSD11B1 (0.50) | HSD11B1CRHR1AHRKDM4EHSP90AA1 | |
| SCHEMBL464507 | 0.76 | AHR (0.64) | HSD11B1CRHR1AHRKDM4EHSP90AA1 | |
| SCHEMBL29624840 | 0.76 | AHR (0.64) | HSD11B1CRHR1AHRKDM4EHSP90AA1 | |
| SCHEMBL6027697 | 0.73 | ALDH1A1 (0.56) | KDM4EHSP90AA1ALDH1A1TSHRALPL | |
| SCHEMBL10852761 | 0.73 | KDM4E (0.46) | HSD11B1AHRKDM4EHPGDKMT2A | |
| SCHEMBL3761176 | 0.72 | CRHR1 (0.53) | HSD11B1CRHR1AHRKDM4EALDH1A1 | |
| SCHEMBL2907836 | 0.70 | MAPK1 (0.56) | HSD11B1ALDH1A1HPGDTSHR | |
| SCHEMBL4338636 | 0.70 | HSD11B1 (0.47) | HSD11B1CRHR1AHRKDM4EHSP90AA1 | |
| SCHEMBL8746755 | 0.70 | MAPT (0.49) | HSD11B1CRHR1AHRHSP90AA1HSP90AB1 | |
| SCHEMBL11553551 | 0.69 | HSD11B1 (0.46) | HSD11B1AHRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110072844-B | Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni | 英特维特国际股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-110300578-B | Compounds for the treatment of respiratory diseases in cattle or pigs | 英特维特国际股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220041547-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | INTERVET INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | INTERVET INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3810571-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| EP-3810576-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | Intervet International B.V. (NL) | 2021-04-28 | — | — | EP | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HSD11B1 2525/4885CRHR1 4850/4885AHR 1087/4885 |
| US-12077488-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | SORD, HEXD, SNRPD1 | HSD11B1 154/4885CRHR1 2390/4885AHR 1064/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | HSD11B1 2200/4885CRHR1 4837/4885AHR 830/4885 |
| US-20220041547-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | SORD, HEXD, SNRPD1 | HSD11B1 154/4885CRHR1 2390/4885AHR 1064/4885 |
| US-11034650-B2 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | HEXD, SORD, SDHA | HSD11B1 87/4885CRHR1 2098/4885AHR 1001/4885 |
| US-20210347730-A1 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, PPARD | HSD11B1 81/4885CRHR1 1939/4885AHR 1062/4885 |
| US-20210292284-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF INFECTION WITH MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI | SORD, HEXD, SDHA | HSD11B1 237/4885CRHR1 2301/4885AHR 1163/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | HSD11B1 2232/4885CRHR1 4372/4885AHR 4859/4885 |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | HSD11B1 87/4885CRHR1 2089/4885AHR 4356/4885 |
| US-20230000813-A1 | COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | PIGS, BTD, BRD1 | HSD11B1 72/4885CRHR1 2462/4885AHR 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.